EIM
JNCE

Essex Investment Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Essex Investment Management’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-72,607
Closed -$592K – 520
2020
Q3 		$592K Hold
72,607
– – 0.08% 283
2020
Q2 		$501K Sell
72,607
-35,597
-33% -$192K 0.08% 257
2020
Q1 		$514K Hold
108,204
– – 0.1% 216
2019
Q4 		$945K Hold
108,204
– – 0.12% 239
2019
Q3 		$360K Buy
+108,204
New +$433K 0.05% 315

Other funds holding JNCE

TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Essex Investment Management's JNCE Position: Q4 2020 in Review

Essex Investment Management sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q4 2020, closing a stake of 72,607 shares — an estimated $592K sold.

Essex Investment Management first reported a position in JNCE in Q3 2019 and held it in 5 quarters. The position peaked at $945K in Q4 2019. 104 funds tracked by Wall St. Rank hold JNCE as of Q4 2020.

  • Essex Investment Management reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Essex Investment Management sold 72,607 Jounce Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $592K.
  • Essex Investment Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q3 2019 and held it in 5 quarters.
  • Essex Investment Management's Jounce Therapeutics, Inc. Common Stock position peaked at $945K in Q4 2019.
  • 104 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q4 2020.

Based on Essex Investment Management's 13F filing for Q4 2020, filed 12 Feb 2021.